Proprietary portfolio

We develop superior therapeutics that are clinically derisked and address unmet patient need in high value markets including diabetes and other cardiometabolic diseases, based on our Arestat® technology platform

OUR PORTFOLIO

Partnering

We partner with leading pharmaceutical and medtech companies to develop superior therapeutic profiles, leveraging our innovative and proprietary formulation and drug delivery technology

PARTNERING

Validated technology

Our development expertise is underpinned by our world-leading Arestat® technology platform, protected by a robust intellectual property portfolio

OUR TECHNOLOGY

Latest News

  • 30th July 2026

    Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

    CLICK HERE
  • 3rd August 2026

    Clarivate report – Companies to Watch 2026: Seven innovators shaping next-generation obesity therapies

    CLICK HERE
  • 18th May 2026

    Upcoming conference attendance

    ↓ DOWNLOAD PDF